MLKL-IN-6
MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL) . MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects[1].
Product Specifications
UNSPSC
12352005
Target
Mixed Lineage Kinase; Necroptosis
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/mlkl-in-6.html
Purity
98.57
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(OC)/C=C/C(N1C)=NC(N(CC#CC2=CC=CC(O)=C2)C(N3C)=O)=C1C3=O
Molecular Formula
C20H18N4O5
Molecular Weight
394.38
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Human Vacuolar-sorting protein SNF8
Recombinant Human immunodeficiency virus type 1 group M subtype B Protein Rev (rev)
Recombinant Human immunodeficiency virus type 1 group M subtype B Protein Rev (rev)
Recombinant Human immunodeficiency virus type 1 group M subtype B Protein Rev (rev)
